Global /China /Healthcare /Biotechnology /688319

Chengdu Olymvax Biopharmaceuticals Inc.

688319

• SSE: 688319 • Delayed

30.88CNY 3.1%

4.56 USD

As of 16 June 2026, Chengdu Olymvax Biopharmaceuticals Inc. has a market cap of $1.79B USD, ranking #7582 globally and #1902 in China. It ranks #616 in the Healthcare sector, and #116 in the Biotechnology industry.

Global Rank

7582

Country Rank

1902

Sector Rank

616

Industry Rank

116

Key Stats

Market Cap

$1.79BUSD

12.15B CNY

Enterprise Value

$1.82BUSD

12.33B CNY

Revenue (TTM)

$104.05MUSD

704.16M CNY

EBITDA (TTM)

$9.78MUSD

66.2M CNY

Net Income (TTM)

$3.29MUSD

22.26M CNY

EBITDA Margin

9.4%

Profit Margin

3.2%

PE Ratio

545.7

Forward PE

166.3

PS Ratio

17.3

PB Ratio

13.4

EV/EBITDA

175.0

Company Profile

Country (HQ)

China

Sector

Healthcare

Industry

Biotechnology

CEO

Shaowen Fan open_in_new

Employees

451

Founded

2009

Website

olymvax.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
3.1%	-1%	0.7%	20%	29%	18%	90%	45%	3.3%

News

Markets

Exchange	Ticker	Price	Quotes
Shanghai Stock Exchange (SSE / SHA) MIC: XSHG PRIMARY	688319 成都欧林生物科技股份有限公司 Class A ISIN: CNE1000051H8 Shares Out.: Shares Outstanding: 405.409M¹ Shares Float: 244.45M² TV: TradingView: SSE: 688319 SA: Stock Analysis: SHA: 688319 YF: Yahoo Finance: 688319.SS GF: Google Finance: SHA: 688319 BA: Barron's: 688319 MS: Morningstar: XSHG: 688319	30.88 CNY	TV: TradingView: SSE: 688319 SA: Stock Analysis: SHA: 688319 YF: Yahoo Finance: 688319.SS GF: Google Finance: SHA: 688319 BA: Barron's: 688319 MS: Morningstar: XSHG: 688319

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About Chengdu Olymvax Biopharmaceuticals Inc.

Chengdu Olymvax Biopharmaceuticals Inc. engages in the research and development, production, and sales of vaccines for human use in China. The company offers absorbed tetanus vaccine, group a and group c products; and haemophilus influenzae type b products. The company was founded in 2009 and is based in Chengdu, China.

Similar Companies

Industry: Biotechnology (China)

Name	Market Cap (USD) diff.	PE	Country
WuXi Biologics (Cayman) Inc. SHEK: 2269	$17.45B 136.71B HKD 872%	25.3	China
CSPC Pharmaceutical Group Ltd. SHEK: 1093	$12.2B 95.58B HKD 580%	22.1	China
Sichuan Kelun Pharmaceutical Co., Ltd. SHE: 002422	$8.01B 54.23B CNY 346%	34.4	China
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. SSE: 603392	$7.34B 49.69B CNY 309%	-	China
3SBio Inc. SHEK: 1530	$7.08B 55.5B HKD 295%	5.8	China
Hangzhou Tigermed Consulting Co., Ltd. SHE: 300347	$6.73B 45.52B CNY 275%	61.6	China

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 10K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 9K%	19.0	United States
argenx SE EBR: ARGX	$47.89B 41.39B EUR 3K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.92B 68.19T KRW 2K%	35.5	South Korea
CSL Ltd. ASX: CSL	$42.46B 60.27B AUD 2K%	29.3	Australia
Lonza Group AG SIX: LONN	$42.17B 33.71B CHF 2K%	37.2	Switzerland

chevron_leftBack